Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic.

Journal Article (Journal Article;Review)

The burden that Parkinson's disease (PD) exacts on the population continues to increase year after year. Though refinement of symptomatic treatments continues at a reasonable pace, no accepted therapies are available to slow or prevent disease progression. The leucine-rich repeat kinase 2 (LRRK2) gene was identified in PD genetic studies and offers new hope for novel therapeutic approaches. The evidence linking LRRK2 kinase activity to PD susceptibility is presented, as well as seminal discoveries relevant to the prosecution of LRRK2 kinase inhibition. Finally, suggestions are made for predictive preclinical modeling and successful first-in-human trials.

Full Text

Duke Authors

Cited Authors

  • West, AB

Published Date

  • February 2015

Published In

Volume / Issue

  • 30 / 2

Start / End Page

  • 180 - 189

PubMed ID

  • 25448543

Pubmed Central ID

  • PMC4318704

Electronic International Standard Serial Number (EISSN)

  • 1531-8257

Digital Object Identifier (DOI)

  • 10.1002/mds.26075


  • eng

Conference Location

  • United States